Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

被引：2

作者：

Timmerman, John ^{[1
]}

Lavie, David ^{[2
]}

Johnson, Nathalie A. ^{[3
]}

Avigdor, Abraham ^{[4
]}

Borchmann, Peter ^{[5
]}

Andreadis, Charalambos ^{[6
]}

Bazargan, Ali ^{[7
,8
]}

Gregory, Gareth P. ^{[9
]}

Keane, Colm ^{[10
]}

Tzoran, Inna ^{[11
]}

Vucinic, Vladan ^{[12
]}

Zinzani, Pier Luigi ^{[13
,14
]}

West, Rachel Marceau ^{[15
]}

Pillai, Pallavi ^{[15
]}

Marinello, Patricia ^{[15
]}

Herrera, Alex F. ^{[16
]}

机构：

[1] UCLA, Med Ctr, Los Angeles, CA USA

[2] Hadassah Med Ctr, Jerusalem, Israel

[3] Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ, Canada

[4] Sheba Med Ctr Tel HaShomer, Ramat Gan, Israel

[5] Univ Hosp Cologne, Cologne, Germany

[6] UCSF, San Francisco, CA USA

[7] Univ Melbourne, Melbourne, Vic, Australia

[8] St Vincents Hosp, Fitzroy, Vic, Australia

[9] Monash Univ, Sch Clin Sci, Monash Hlth, Melbourne, Australia

[10] Princess Alexandra Hosp, Brisbane, Qld, Australia

[11] Rambam Hlth Care Campus, Haifa, Israel

[12] Univ Leipzig, Med Ctr, Clin & Policlin Hematol Cell Therapy & Hemostaseo, Leipzig, Germany

[13] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[14] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy

[15] Merck & Co Inc, Rahway, NJ USA

[16] City Hope Natl Med Ctr, Duarte, CA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182019

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[21] Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Hutchings, Martin
Mous, Rogier
Clausen, Michael Roost
Johnson, Peter
Linton, Kim M.
Chamuleau, Martine E. D.
Lewis, David John
Balari, Anna Sureda
Cunningham, David
Oliveri, Roberto S.
Elliott, Brian
DeMarco, Dena
Azaryan, Ada
Chiu, Christopher
Li, Tommy
Chen, Kuo-mei
Ahmadi, Tahamtan
Lugtenburg, Pieternella J.
LANCET, 2021, 398 (10306): : 1157 - 1169
[22] Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study
Locatelli, Franco
Mauz-Koerholz, Christine
Neville, Kathleen
Llort, Anna
Beishuizen, Auke
Daw, Stephen
Pillon, Marta
Aladjidi, Nathalie
Klingebiel, Thomas
Landman-Parker, Judith
Medina-Sanson, Aurora
August, Keith
Sachs, Jessica
Hoffman, Kristen
Kinley, Judith
Song, Sam
Song, Gregory
Zhang, Stephen
Suri, Ajit
Gore, Lia
LANCET HAEMATOLOGY, 2018, 5 (10): : E450 - E461
[23] High Complete Response Rates With Pembrolizumab in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma: Results of an Open-Label, Phase 2 Study
Martin, Peter
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 6 - 7
[24] An open-label, single-arm phase II study of everolimus (RAD001) in patients with relapsed/refractory classical Hodgkin lymphoma (HL)
Johnston, P. B.
Lewis, L. T.
Rogerio, J. W.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[25] A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
Lin, Chia-Chi
Garralda, Elena
Schoeffski, Patrick
Hong, David S.
Siu, Lillian L.
Martin, Miguel
Maur, Michela
Hui, Rina
Soo, Ross A.
Chiu, Joanne
Zhang, Tian
Ma, Brigette
Kyi, Chrisann
Tan, Daniel S. W.
Cassier, Philippe A.
Sarantopoulos, John
Weickhardt, Andrew
Carvajal, Richard D.
Spratlin, Jennifer
Esaki, Taito
Rolland, Frederic
Akerley, Wallace
Deschler-Baier, Barbara
Rispoli, Lawrence
Samant, Tanay S.
Chowdhury, Niladri Roy
Gusenleitner, Daniel
Kwak, Eunice L.
Askoxylakis, Vasileios
De Braud, Filippo
ONCOIMMUNOLOGY, 2024, 13 (01):
[26] Everolimus (EVE) for relapsed/refractory classical Hodgkin lymphoma (cHL): Open-label, single-arm, phase II study.
Johnston, Patrick B.
Pinter-Brown, Lauren C.
Rogerio, Jaqueline Willemann
Warsi, Ghulam
Chau, Quincy
Ramchandren, Rod
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[27] A Phase 2, Open-Label, Multicenter Study of Tazemetostat in Combination with Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma
Patel, Krish
Bailey, Neil
Pagel, John M.
BLOOD, 2020, 136
[28] KEYNOTE B68: Open-label phase 2 study of the efficacy and safety of pembrolizumab administered every six weeks in patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma.
Armand, Philippe
Pathiraja, Kumudu
Chakraborty, Samhita
Marinello, Patricia
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[29] Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies
Hamid, O.
Chow, L. Q.
Sanborn, R. E.
Marshall, S.
Black, C.
Gribbin, M.
McDevitt, J.
Karakunnel, J. J.
Gray, J. E.
ANNALS OF ONCOLOGY, 2016, 27
[30] Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Coyle, Luke
Morley, Nicholas J.
Rambaldi, Alessandro
Mason, Kylie D.
Verhoef, Gregor
Furness, Caroline
Desai, Rajendra
Mergen, Noemi
BLOOD, 2020, 136

← 1 2 3 4 5 →